RESUMO
The aim of this study was to develop a stable parenteral dosage form for the investigational cytotoxic drug [Arg6, D-Trp79,MePhe8]-Substance P [6-11] (Substance P Antagonist G; Antagonist G). Antagonist G bulk drug was structurally and analytically characterized. The drug exhibits excellent aqueous solubility, although relatively poor aqueous stability characteristics. Lyophilization was, therefore, selected as the manufacturing process. Differential scanning calorimetry studies were conducted to determine the freeze-drying cycle parameters which resulted in a stable, lyophilized formulation of Antagonist G. The prototype, containing 50 mg Antagonist G per vial, was found to be the optimal formulation in terms of solubility, length of the freeze-drying cycle, stability, and dosage requirements in the planned phase I clinical trials. Quality control of the freeze-dried formulation showed that the manufacturing process does not change the integrity of Antagonist G. Shelf life studies demonstrated that the formulation is stable for at least 3 years, when stored at 2-8 degrees C in a dark environment. Oxidative degradation products of Antagonist G were isolated and structurally characterized by mass spectrometry, nuclear magnetic resonance spectroscopy, and infrared spectroscopy.
Assuntos
Antineoplásicos/química , Química Farmacêutica/métodos , Neuropeptídeos/antagonistas & inibidores , Fragmentos de Peptídeos/química , Substância P/análogos & derivados , Sequência de Aminoácidos , Antineoplásicos/metabolismo , Cromatografia Líquida de Alta Pressão , Estabilidade de Medicamentos , Liofilização , Infusões Parenterais , Espectroscopia de Ressonância Magnética , Estrutura Molecular , Oxirredução , Fragmentos de Peptídeos/metabolismo , Substância P/química , Substância P/metabolismoRESUMO
A stable parenteral dosage form for the investigational cytotoxic drug clanfenur was designed, and the bulk drug was characterized by its nuclear magnetic resonance, mass spectrometry, infrared, and ultraviolet spectra. The 1H and 13C spectra show clanfenur to be a mixture of two stereoisomers. Because of poor solubility in aqueous solution and precipitation in co-solvent, surfactant, or emulsion systems, a two-pump infusion system was developed for intravenous administration. Clanfenur, solubilized in a Cremophor EL/ethanol (1:1, w/v) solution (concentration, 15 mg/mL), can be simultaneously infused with 5% dextrose infusion fluid. Total doses of up to 1,680 mg of clanfenur (and 56 g of Cremophor EL) theoretically can be administered to patients over a 6-hour period. From accelerated stability testing of clanfenur in the Cremophor EL/ethanol (1:1, w/v) formulation, a shelf life of 3.5 years at 4 degrees C and of 4 months at 25 degrees C is calculated.
Assuntos
Antineoplásicos/administração & dosagem , Antineoplásicos/análise , Diflubenzuron/análogos & derivados , Drogas em Investigação/administração & dosagem , Antineoplásicos/química , Química Farmacêutica , Cromatografia Líquida de Alta Pressão , Diflubenzuron/administração & dosagem , Diflubenzuron/análise , Diflubenzuron/química , Formas de Dosagem , Estabilidade de Medicamentos , Drogas em Investigação/análise , Drogas em Investigação/química , Infusões Intravenosas , Infusões Parenterais , Espectroscopia de Ressonância Magnética , Espectrometria de Massas , Solubilidade , Soluções/química , Espectrofotometria , EstereoisomerismoRESUMO
The pharmaceutical development of the investigational cytotoxic drug EO9 included the structural characterization of the bulk drug by nuclear magnetic resonance (NMR) spectroscopy, mass spectrometry (MS) and infrared (IR) spectroscopy, and analytical characterization by high-performance liquid chromatography and ultraviolet/visible spectrophotometry. The presence of impurities in the bulk drug was investigated. The intermediates in the synthesis of EO9 were structurally characterized by NMR spectroscopy and MS, and analytically characterized by HPLC analysis with photodiode array (PDA) detection. All of the intermediates were below their limits of detection in EO9 bulk drug. The amounts of residual organic solvents were determined by gas chromatography. Methanol and ethanol were detected, but the amounts present did not exceed the limits as set in the United States Pharmacopeia XXII.
Assuntos
Antineoplásicos/isolamento & purificação , Aziridinas/isolamento & purificação , Indolquinonas , Indóis/isolamento & purificação , Antineoplásicos/síntese química , Aziridinas/síntese química , Química Farmacêutica/métodos , Química Farmacêutica/normas , Indóis/síntese química , Espectroscopia de Ressonância Magnética , Espectrometria de Massas , Controle de Qualidade , Espectrofotometria UltravioletaRESUMO
The stability of carzelesin in a polyethylene glycol 400 (PEG 400)/absolute ethanol/polysorbate 80 (Tween 80) (6:3:1, v/v/v) formulation (PET formulation) was investigated as a function of the inter-batch variability of the three excipients. Twenty different PET formulations were tested and the stability of carzelesin in the PET formulation was found to be influenced by the type of PEG 400 used. Subsequent investigations showed that the pH of PEG 400, and consequently the pH of the PET formulation, was responsible for the variable stability characteristics of carzelesin in the PET formulation. The higher the pH of the PET formulation, the higher the rate of degradation of carzelesin in PET. The major degradation products were found to be U-76,073 and U-76,074.
Assuntos
Antineoplásicos/química , Benzofuranos/química , Excipientes/química , Indóis/química , Química Farmacêutica , Cromatografia Líquida de Alta Pressão , Estabilidade de Medicamentos , Duocarmicinas , Etanol/química , Concentração de Íons de Hidrogênio , Polietilenoglicóis/química , Polissorbatos/química , Reprodutibilidade dos TestesRESUMO
The aim of this study was to design a parenteral dosage form for the investigational cytotoxic drug carzelesin. A stable formulation in PET (Polyethylene glycol 400/absolute ethanol/Tween 80, 6:3:1, v/v/v) was developed. The prototype, containing 0.50 mg carzelesin in 2.0 ml PET formulation, was found to be the optimal formulation in terms of solubility, stability and dosage requirements in phase I clinical trials. Quality control of the formulation showed that the pharmaceutical preparation of carzelesin in PET is not negatively influenced by the manufacturing process. Shelf life studies demonstrated that the formulation is stable for at least 1 year, when stored at -30 degrees C in the dark. In addition, the stability of carzelesin in the PET formulation is discussed as a function of temperature, additives and after dilution in infusion fluids.
Assuntos
Antineoplásicos/química , Benzofuranos/química , Indóis/química , Antineoplásicos/administração & dosagem , Antineoplásicos/análise , Benzofuranos/administração & dosagem , Benzofuranos/análise , Química Farmacêutica , Cromatografia Líquida de Alta Pressão , Estabilidade de Medicamentos , Duocarmicinas , Etanol , Indóis/administração & dosagem , Indóis/análise , Infusões Parenterais , Espectroscopia de Ressonância Magnética , Polietilenoglicóis , Polissorbatos , Controle de Qualidade , Espectrometria de Massas de Bombardeamento Rápido de Átomos , EspectrofotometriaRESUMO
The aim of this study was to design a stable parenteral dosing form of the investigational cytotoxic drug, encoded EO9. EO9 exhibits poor aqueous solubility and stability characteristics. Freeze-drying was selected as the manufacturing process. Differential scanning calorimetry studies were conducted to determine the freeze-drying cycle parameters. A stable lyophilized formulation of EO9 was developed. The prototype, containing 8.0 mg EO9 and 200 mg lactose/vial, was found to be the optimal formulation in terms of solubility, length of the freeze-drying cycle, stability, and dosing requirements for phase I clinical trials. Quality control of the freeze-dried formulation showed that the manufacturing process does not change the integrity of EO9. Shelf-life studies demonstrated that the formulation remains stable for at least 1 year when stored at +4 degrees C in a dark environment.